BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BioCentury | Aug 10, 2018
Clinical News

Athenex's actinic keratosis ointment meets in pair of Phase III trials

Athenex Inc. (NASDAQ:ATNX) said KX2-391 (KX-01) met the primary endpoint of improving the proportion of patients who achieved complete clearance of actinic keratosis (AK) lesions within the face or scalp treatment areas at day 57...
BioCentury | Dec 15, 2017
Company News

Athenex grants Almirall rights to KX2-391

Athenex Inc. (NASDAQ:ATNX) granted Almirall S.A. (Madrid:ALM) exclusive rights to develop and commercialize KX2-391 (KX-01) in the U.S. and parts of Europe, including Russia. Athenex will receive $55 million up front and is eligible for...
BioCentury | Nov 10, 2017
Product R&D

Blueprint gets the GIST

...was 150-fold more potent for c-Kit-mutant D816V than three targets of other RTK inhibitors, VEGFR-2, CSK...
...BCR-ABL tyrosine kinase c-Kit (KIT; CD117) - Stem cell factor receptor tyrosine kinase CSK - c-src tyrosine kinase...
BioCentury | Jun 14, 2017
Financial News

Athenex ticks up after $66M IPO

Cancer company Athenex Inc. (NASDAQ:ATNX) gained $1.56 (14%) to $12.56 in its first day of trading Thursday after it raised $66 million through the sale of 6 million shares at $11 in an IPO underwritten...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

...Nature in 2003. That accomplishment helped attract an additional W4 billion ($4 million) investment from CSK...
BioCentury | Mar 24, 2016
Distillery Therapeutics

Therapeutics: Cytochrome P450 3A5 (CYP3A5)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest inhibiting CYP3A5 could help treat drug-resistant pancreatic ductal adenocarcinoma (PDAC). In patient-derived PDAC cell lines, high expression of CYP3A5 in one cell subtype was associated...
BioCentury | Feb 8, 2016
Strategy

Worldwide web

Korean biotech Hanmi Pharmaceutical Co. Ltd. is on a mission to globalize. And with six out-licensing deals announced last year, the company appears to be reaping the rewards of its investment in both new technology...
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
BioCentury | Jul 31, 2014
Translation in Brief

Translational tidbits

...to treat diabetes Phase II to treat idiopathic intracranial hypertension University of Sheffield Saracatinib (AZD0530) c-Src tyrosine kinase (CSK)...
Items per page:
1 - 10 of 36